21/39US=69 / Câncer
Craft BS, Moulder S. Targeted therapy in breast cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 43-59. ISBN 978-1-60327-423-4.

TERAPIA-ALVO NO CANCRO DA MAMA; CANCER DE MAMA; TERAPIA BIOLOGICA; TERAPIA-ALVO; TERAPIA ADJUVANTE; DOENCA METASTATICA


22/39US=69 / Câncer
Kopetz S. Targeted therapy in colorectal cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 101-23. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; CANCER COLORRETAL; EGFR; VEGF; ANTICORPOS MONOCLONAIS


23/39US=69 / Câncer
Stewart DJ. Targeted therapy in non-small cell lung cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 125-56. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; NAO-PEQUENAS DE CANCER DE PULMAO DE CELULAS; EGFR; ERLOTINIB; GEFITINIB; VEGFR


24/39US=69 / Câncer
Zhou Y, Alexanian R, Wang M. Targeted therapy in multiple myeloma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 213-36. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; MIELOMA MULTIPLO; PATOGENESE MOLECULAR; MICROAMBIENTE


25/39US=69 / Câncer
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J. Targeted therapy in myelodysplastic syndrome. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 237-60. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; SINDROME MIELODISPLASICA; DECITABINA; A METILACAO DO DNA; 5-AZACITIDINA; LENALIDOMIDA


26/39US=69 / Câncer
Markman M. Targeted therapy in epithelial ovarian cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 261-9. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; CANCER EPITELIAL DE OVARIO; CANCRO DO OVARIO; CISPLATINA; CARBOPLATINA; AGENTES ANTI-ANGIOGENICOS; BEVACIZUMAB


27/39US=69 / Câncer
Gibbons DL, Wolff RA, Varadhachary G. Targeted drug therapy in pancreatic cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 271-87. ISBN 978-1-60327-423-4.

TERAPIA MEDICAMENTOSA ALVO DE CANCER DE PANCREAS; TERAPIA-ALVO; CANCER DE PANCREAS; QUIMIOTERAPIA; ENSAIOS CLINICOS


28/39US=69 / Câncer
Zurita AJ, Ward JF, Kim J. Targeted therapy in prostate cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 289-304. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; CANCER DE PROSTATA; CANCER DE PROSTATA; NEOPLASIA DE PROSTATA; RESISTENTE A CASTRACAO CANCRO DA PROSTATA; ANDROGENO RECEPTOS; ANSAMICINAS; MTOR; ANGIOGENESE; IMUNOTERAPIA


29/39US=69 / Câncer
Jonasch E, Tannir N. Targeted therapy in renal cell carcinoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 305-16. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; CARCINOMA DE CELULAS RENAIS; MUTACAO BVS; ANTIVASCULAR TERAPIA; TERAPEUTICA DE COMBINACAO; TERAPIA SEQUENCIAL


30/39US=69 / Câncer
Hong D, Chintala L. Combining targeted therapies. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 361-81. ISBN 978-1-60327-423-4.

COMBINANDO TERAPIAS-ALVO; TERAPIA-ALVO; TERAPIA PERSONALIZADA; VIAS DE SINALIZACAO; RESISTENCIA A DROGAS; DESENVOLVIMENTO DE DROGAS


31/39US=69 / Câncer
Camacho LH. Drug development in cancer medicine: challenges for targeted approaches. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 383-410. ISBN 978-1-60327-423-4.

DESENVOLVIMENTO DE DROGAS EM CANCER; TERAPIA-ALVO; DESAFIOS; OBSTACULOS; DESENVOLVIMENTO DE DROGAS; ENSAIOS CLINICOS; FASE I


32/39US=69 / Câncer
Welsh SJ, Powis G. Toward personalized therapy for cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 411-25. ISBN 978-1-60327-423-4.

TERAPIA PERSONALIZADA PARA O CANCER; CANCER; MEDICINA PERSONALIZADA; TERAPIA INDIVIDUALIZADA; FARMACOGENOMICA; TERAPIA-ALVO; ALVOS MOLECULARES


33/39US=80 / Biol/Mol
Alaoui-Jamali MA, Pinto D. Proteomic profiling of tyrosine kinases as pharmacological endpoints for targeted cancer therapy. In: Daoud SS. Cancer proteomics from bench to bedside. New Jersey: Humana press, 2008. p. 59-77. (Cancer Drug Discovery and Development) ISBN 978-1-59745-169-7.

TIROSINA-QUINASES PROTEICAS; CANCER; TERAPIA-ALVO; PROTEOMICA


34/39US=84-A / Biol/Mol
Micke P, Moustakas A, Ohshima M, Kappert K. Transformig growth factor-B in developing and advanced cancers: cancer-associated fibroblasts and the role of TGF-B. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 417-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

ASSOCIADAS CANCER FIBROBLASTOS; ESTROMA; ASSOCIADAS CANCER FIBROBLASTOS; TUMOR DO ESTROMA INTERACCAO; MIOFIBROBLASTOS; TERAPIA-ALVO; TGFB-1; MICROARRAY; EXPRESSAO DO GENE; CANCER


35/39US=1 / Quimioterapia
Esper P. Targeted therapy. In: Gullatte MM, editor. Clinical guide to antineoplastic therapy: a chemotherapy handbook. 2nd ed. Pittsburgh: Oncology Nursing Society, 2007. p. 57-75. ISBN 978-1-890504-68-7.

TERAPIA-ALVO; TERAPIA DO CANCER; HISTORIA TERAPIAS-ALVO; EVOLUCAO DE TERAPIAS-ALVO; ALVO RECEPTORES DA SUPERFICIE CELULAR; PAPEL DO ENFERMEIRO DE ONCOLOGIA EM TERAPIA-ALVO; PACIENTE E EDUCACAO FAMILIAR


36/39US=21 / Neurologia
Vogelbaum M, Thomas T. Contemporary investigational treatments: small molecule agents. In: Barnett GH. High-grade gliomas: diagnosis and treatment. New Jersey: Humana Press, 2007. p. 337-56. (Current Clinical Oncology) ISBN 978-1-58829-511-8.

GLIOMA DE ALTO GRAU. TERAPIA; AGENTES MOLECULARES; INIBIDORES DE GLIOMA; FATORES DE CRESCIMENTO; DROGAS DE MOLECULAS PEQUENAS; TERAPIA-ALVO; INIBIDORES DE QUINASE DE TIROSINA


37/39US=46 / Câncer
Reiter Y, Lev A. Immunotoxins and recombinant immunotoxins in cancer therapy. In: Meyers RA. Cancer: from mechanisms to therapeutic approaches. New Jersey: Wiley-Blackwell, 2007. p. 409-41. ISBN 978-3-527-31768-4.

IMUNOTOXINAS; IMUNOTOXINAS RECOMBINANTES EM TERAPIA DO CANCER; TERAPIA DO CANCER; IMMUNOTOXINS; ANTICORPOS RECOMBINANTES; TERAPIA-ALVO


38/39US=92 / Biol/Mol
Deininger M. Established cancer therapies: tyrosine kinase inhibitors. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 477-508. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

TERAPIA-ALVO; BCR-ABL; FLT3; EGFR; TYROSISE INIBITORS QUINASE; IMATINIB; GEFITINIB; ERLOTINIB; CANCER; LEUCEMIA


39/39US=92 / Biol/Mol
Furman RR, Leonard JP, Decter J, Coleman M. Recent and developing cancer therapies: monoclonal antibodies in lymphomas. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 511-36. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

ANTICORPOS MONOCLONAIS; IMUNOTERAPIA; TERAPIA-ALVO


Primeira | Anterior | Próxima | Última